The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

Zhi Qiang Wang, Fei Zhang, Ting Deng, Le Zhang, Fen Feng, Feng Hua Wang, Wei Wang, De Shen Wang, Hui Yan Luo, Rui Hua Xu, Yi Ba, Yu Hong Li

    Research output: Contribution to journalArticle

    Abstract

    Background: Oxaliplatin, irinotecan, 5-fluorouracil, and l-leucovorin (FOLFIRINOX) has become one of the first-line treatment options for advanced pancreatic cancer (PC). However, the relatively high rate of grade 3 or 4 adverse events associated with the standard dosage of FOLFIRINOX limits its widespread use in clinical practice. In this study, we were to evaluate the efficacy and safety of a modified FOLFIRINOX regimen as a first-line chemotherapy for Chinese patients with metastatic PC. Methods: Patients with histologically confirmed primary metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 were recruited to receive the modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m 2 ; irinotecan, 150 mg/m 2 ; l-leucovorin, 200 mg/m 2 ; and 5-fluorouracil, 2400 mg/m 2 , repeated every 2 weeks). The treatment was continued for 12 cycles unless the patient had progressive disease (PD), stable disease (SD) with symptom deterioration, unacceptable adverse events, or requested to terminate the treatment prematurely. The primary endpoint was objective response rate (ORR). Results: Sixty-five patients were enrolled from July 2012 to April 2017 in three institutions, and they all received at least one cycle of chemotherapy, with a median of 8 cycles (range 1-12 cycles). No complete response was observed. Twenty-one (32.3%) patients had partial responses, and 27 (41.5%) had SD. The ORR and disease control rate of the study cohort was 32.3% and 73.8%. The estimated median overall survival and progression-free survival were 11.60 (95% confidence interval [CI] 8.76-14.44) and 5.77 (95% CI 5.00-6.54) months. Major grade 3 or 4 adverse events included neutropenia (12.3%) and diarrhea (6.2%). No treatment-related death was observed. Conclusions: Modified FOLFIRINOX was well-tolerated and might be a promising option as first-line therapy for Chinese patients with metastatic PC. Trial registration ClinicalTrials.gov, NCT02028806. Registered 7 January 2014, https://clinicaltrials.gov/ct2/show/NCT02028806

    Original languageEnglish (US)
    Article number26
    JournalCancer Communications
    Volume39
    Issue number1
    DOIs
    StatePublished - May 8 2019

      Fingerprint

    Keywords

    • Chemotherapy
    • Dose modification
    • Efficacy
    • FOLFIRINOX
    • First-line
    • Metastatic
    • Multicenter
    • Overall response rate
    • Pancreatic cancer
    • Safety

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Wang, Z. Q., Zhang, F., Deng, T., Zhang, L., Feng, F., Wang, F. H., Wang, W., Wang, D. S., Luo, H. Y., Xu, R. H., Ba, Y., & Li, Y. H. (2019). The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Communications, 39(1), [26]. https://doi.org/10.1186/s40880-019-0367-7